InsightfulValue
← Home

GlaxoSmithKline
GlaxoSmithKline

Pharma / Pharma and biotechnology


πŸ”§ Tools

βœ… Due Diligence
Company at a Glance

GlaxoSmithKline

πŸ“Š Get full analytics about GlaxoSmithKline

Sign up for free or log in

✍️ Sign up to get "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" for free

Price
Live  
Overview
GlaxoSmithKline (GSK) is a multinational pharmaceutical and healthcare company headquartered in Brentford, London. The company was formed in 2000 through the merger of British company Glaxo Wellcome and American company SmithKline Beecham. It is one of the largest pharmaceutical companies in the world and is focused on the research, development, and marketing of prescription medicines, vaccines, and consumer healthcare products.
History:
The history of GlaxoSmithKline can be traced back to the establishment of two independent companies: Joseph Nathan and Co. in New Zealand in 1873 and Burroughs Wellcome & Company in the UK in 1880. In 1995, Glaxo Wellcome PLC was formed through the merger of Glaxo and Burroughs Wellcome. SmithKline Beecham PLC was formed in 1989 through the merger of SmithKline Beckman Corporation and Beecham Group PLC. In 2000, the two companies merged to form GlaxoSmithKline.
Products:
GSK's product portfolio includes prescription medicines, vaccines, and consumer healthcare products. Its prescription medicines cover a broad range of therapeutic areas, including respiratory, HIV, oncology, and neurosciences. The company also offers vaccines for diseases such as influenza, meningitis, and shingles. Its consumer healthcare products include over-the-counter medicines, oral care, nutrition, and skin health products.
Research and Development:
GSK has a strong focus on research and development (R&D) and invests heavily in this area. The company has R&D facilities in the UK, US, Belgium, and China, among others. Its R&D efforts are focused on discovering and developing new medicines and vaccines for a wide range of diseases and conditions. GSK collaborates with academic institutions, governments, and other industry partners to advance its research efforts.
Corporate Responsibility:
GSK is committed to operating ethically and responsibly, with a focus on sustainability and corporate social responsibility. The company has various initiatives in place to reduce its environmental impact and improve access to healthcare for underserved populations. It also has policies in place to ensure ethical business practices and compliance with laws and regulations.
Financials:
In 2020, GSK reported revenues of Β£34 billion and a net income of Β£5.5 billion. The company employs over 100,000 people globally and has a presence in over 150 countries. Its primary stock exchange listings are on the London Stock Exchange and the New York Stock Exchange.
Partnerships:
GSK has formed partnerships with various organizations to further its research and development efforts, expand its product portfolio, and improve access to healthcare. Some notable collaborations include:
- Joint ventures with Pfizer in the areas of consumer healthcare and HIV treatment
- Collaboration with Sanofi to develop a COVID-19 vaccine
- Partnership with Innoviva to develop respiratory treatments
- Collaboration with Vir Biotechnology to develop pandemic treatments
- Partnership with the Bill & Melinda Gates Foundation to develop vaccines for malaria and tuberculosis
Summary:
GlaxoSmithKline is a multinational pharmaceutical and healthcare company focused on research, development, and marketing of prescription medicines, vaccines, and consumer healthcare products. It has a strong history and presence in the market, with a commitment to corporate responsibility and ethical business practices. The company has a diverse range of products and partnerships that contribute to its strong financial performance.
What is special about the company?
GlaxoSmithKline

πŸ“ˆ Want to read more about GlaxoSmithKline?

Sign up for free or log in

🎁 Free download! "The Checklist Value Investor β€” A Smarter Way to Pick Stocks"

VGhlcmUgYX JlIHNldmVy YWwga2V5IG ZhY3RvcnMg dGhhdCBtYW tlIEdsYXhv U21pdGhLbG luZSAoR1NL KSBhIHVuaX F1ZSBhbmQg c3BlY2lhbC Bjb21wYW55 Ojxicj4xLi BTaXplIGFu ZCBTY29wZT ogR1NLIGlz IG9uZSBvZi B0aGUgbGFy Z2VzdCBwaG FybWFjZXV0 aWNhbCBjb2 1wYW5pZXMg aW4gdGhlIH dvcmxkLCB3 aXRoIG9wZX JhdGlvbnMg aW4gb3Zlci AxNTAgY291 bnRyaWVzIG FuZCBhIHZh c3QgcG9ydG ZvbGlvIG9m IHByb2R1Y3 RzIHNwYW5u aW5nIHByZX NjcmlwdGlv biBtZWRpY2 luZXMsIGNv bnN1bWVyIG hlYWx0aGNh cmUsIGFuZC B2YWNjaW5l cy48YnI+Mi 4gSGlzdG9y eSBhbmQgTG VnYWN5OiBH U0sgaGFzIG EgcmljaCBo aXN0b3J5IG RhdGluZyBi YWNrIHRvIH RoZSAxOXRo IGNlbnR1cn ksIHdpdGgg dGhlIG1lcm dlciBvZiBH bGF4b1dlbG xjb21lIGFu ZCBTbWl0aE tsaW5lIEJl ZWNoYW0gaW 4gMjAwMCBz b2xpZGlmeW luZyBpdHMg cG9zaXRpb2 4gYXMgYSBt YWpvciBwbG F5ZXIgaW4g dGhlIGhlYW x0aGNhcmUg aW5kdXN0cn kuPGJyPjMu IFJlc2Vhcm NoIGFuZCBE ZXZlbG9wbW VudDogSW5u b3ZhdGlvbi BhbmQgcmVz ZWFyY2ggYX JlIGF0IHRo ZSBoZWFydC BvZiBHU0sn cyBidXNpbm Vzcywgd2l0 aCBzaWduaW ZpY2FudCBp bnZlc3RtZW 50cyBtYWRl IGluIGRpc2 NvdmVyaW5n IGFuZCBkZX ZlbG9waW5n IG5ldyBtZW RpY2luZXMg dG8gbWVldC B1bm1ldCBt ZWRpY2FsIG 5lZWRzLjxi cj40LiBDb2 1taXRtZW50 IHRvIEdsb2 JhbCBIZWFs dGg6IEdTSy dzIG1pc3Np b24gaXMgdG 8gaW1wcm92 ZSB0aGUgcX VhbGl0eSBv ZiBodW1hbi BsaWZlIGJ5 IGVuYWJsaW 5nIHBlb3Bs ZSB0byBkby Btb3JlLCBm ZWVsIGJldH RlciwgYW5k IGxpdmUgbG 9uZ2VyLiBU aGUgY29tcG FueSBpcyBk ZWRpY2F0ZW QgdG8gYWRk cmVzc2luZy BnbG9iYWwg aGVhbHRoIG NoYWxsZW5n ZXMsIHN1Y2 ggYXMgaW5m ZWN0aW91cy BkaXNlYXNl cyBhbmQgYW NjZXNzIHRv IGhlYWx0aG NhcmUgaW4g ZGV2ZWxvcG luZyBjb3Vu dHJpZXMuPG JyPjUuIERp dmVyc2UgUG 9ydGZvbGlv OiBHU0sgaG FzIGEgZGl2 ZXJzZSBwb3 J0Zm9saW8g b2YgcHJvZH VjdHMsIGlu Y2x1ZGluZy BtYXJrZXQt bGVhZGluZy BicmFuZHMg c3VjaCBhcy BBZHZhaXIs IFNlbnNvZH luZSwgYW5k IEZsb25hc2 UuIEl0IGFs c28gaGFzIG Egc3Ryb25n IHBpcGVsaW 5lIG9mIHBv dGVudGlhbC BuZXcgbWVk aWNpbmVzIG FuZCB2YWNj aW5lcyBpbi B2YXJpb3Vz IHN0YWdlcy BvZiBkZXZl bG9wbWVudC 48YnI+Ni4g Q29ycG9yYX RlIFJlc3Bv bnNpYmlsaX R5OiBHU0sg aXMgY29tbW l0dGVkIHRv IGNvbmR1Y3 RpbmcgYnVz aW5lc3Mgcm VzcG9uc2li bHkgYW5kIG V0aGljYWxs eSwgd2l0aC BhIGZvY3Vz IG9uIHN1c3 RhaW5hYmls aXR5LCBlbn Zpcm9ubWVu dGFsIHN0ZX dhcmRzaGlw LCBhbmQgaW 1wcm92aW5n IGFjY2Vzcy B0byBoZWFs dGhjYXJlIG ZvciB1bmRl cnNlcnZlZC Bwb3B1bGF0 aW9ucy48Yn I+Ny4gQ3Vs dHVyZSBhbm QgVmFsdWVz OiBHU0sgcH JpZGVzIGl0 c2VsZiBvbi BpdHMgZGl2 ZXJzZSBhbm QgaW5jbHVz aXZlIHdvcm twbGFjZSBj dWx0dXJlLC BndWlkZWQg YnkgYSBzZX Qgb2YgY29y ZSB2YWx1ZX MgdGhhdCBw cmlvcml0aX plIGludGVn cml0eSwgcm VzcGVjdCBm b3IgcGVvcG xlLCBhbmQg dHJhbnNwYX JlbmN5Ljxi cj5PdmVyYW xsLCBHU0sn cyBzaXplLC BoaXN0b3J5 LCBmb2N1cy BvbiBpbm5v dmF0aW9uIG FuZCBnbG9i YWwgaGVhbH RoLCBkaXZl cnNlIHBvcn Rmb2xpbywg Y29tbWl0bW VudCB0byBj b3Jwb3JhdG UgcmVzcG9u c2liaWxpdH ksIGFuZCBz dHJvbmcgY3 VsdHVyZSBt YWtlIGl0IG EgdW5pcXVl IGFuZCBlc3 RlZW1lZCBj b21wYW55IG luIHRoZSBw aGFybWFjZX V0aWNhbCBp bmR1c3RyeS 4=
What the company's business model?
GlaxoSmithKline

πŸ“ˆ Want to read more about GlaxoSmithKline?

Sign up for free or log in

πŸ“– Get insights from "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" now!

R2xheG9TbW l0aEtsaW5l IChHU0spIG lzIGEgZ2xv YmFsIHBoYX JtYWNldXRp Y2FsIGFuZC BoZWFsdGhj YXJlIGNvbX BhbnkgZm9j dXNlZCBvbi BpbXByb3Zp bmcgdGhlIG hlYWx0aCBh bmQgd2VsbC 1iZWluZyBv ZiBwZW9wbG UgYXJvdW5k IHRoZSB3b3 JsZC4gVGhl IGNvbXBhbn kncyBidXNp bmVzcyBtb2 RlbCBpcyBi YXNlZCBvbi Bmb3VyIGtl eSBjb21wb2 5lbnRzOiA8 YnI+MS4gUm VzZWFyY2gg YW5kIERldm Vsb3BtZW50 IChSJkQpOi BHU0sgaW52 ZXN0cyBoZW F2aWx5IGlu IFImRCB0by BkZXZlbG9w IG5ldyBtZW RpY2luZXMs IHZhY2Npbm VzLCBhbmQg Y29uc3VtZX IgaGVhbHRo Y2FyZSBwcm 9kdWN0cy4g VGhlIGNvbX BhbnkgaGFz IHJlc2Vhcm NoIGNlbnRl cnMgYW5kIH BhcnRuZXJz aGlwcyB3b3 JsZHdpZGUg dG8gZHJpdm UgaW5ub3Zh dGlvbiBhbm QgaW1wcm92 ZSBwYXRpZW 50IGhlYWx0 aCBvdXRjb2 1lcy48YnI+ Mi4gQ29tbW VyY2lhbGl6 YXRpb24gYW 5kIE1hcmtl dGluZzogR1 NLIHNlbGxz IGl0cyBwcm 9kdWN0cyB0 byBwYXRpZW 50cywgaGVh bHRoY2FyZS Bwcm9mZXNz aW9uYWxzLC BhbmQgb3Ro ZXIgY3VzdG 9tZXJzIHRo cm91Z2ggYS B2YXJpZXR5 IG9mIGNoYW 5uZWxzLiBU aGlzIGluY2 x1ZGVzIHRy YWRpdGlvbm FsIHNhbGVz IGFuZCBtYX JrZXRpbmcg ZWZmb3J0cy wgYXMgd2Vs bCBhcyBkaW dpdGFsIGFu ZCBlLWNvbW 1lcmNlIGlu aXRpYXRpdm VzLjxicj4z LiBTdHJhdG VnaWMgUGFy dG5lcnNoaX BzOiBHU0sg Y29sbGFib3 JhdGVzIHdp dGggYSByYW 5nZSBvZiBw YXJ0bmVycy wgaW5jbHVk aW5nIGFjYW RlbWljIGlu c3RpdHV0aW 9ucywgYmlv dGVjaCBjb2 1wYW5pZXMs IGFuZCBvdG hlciBwaGFy bWFjZXV0aW NhbCBjb21w YW5pZXMsIH RvIGFkdmFu Y2UgaXRzIH Jlc2VhcmNo IGFuZCBkZX ZlbG9wbWVu dCBlZmZvcn RzLjxicj40 LiBEaXZlcn NpZmllZCBQ b3J0Zm9saW 86IEdTSyBv cGVyYXRlcy BpbiB0aHJl ZSBtYWluIG FyZWFzIC0g cGhhcm1hY2 V1dGljYWxz LCB2YWNjaW 5lcywgYW5k IGNvbnN1bW VyIGhlYWx0 aGNhcmUuIF RoaXMgZGl2 ZXJzaWZpZW QgcG9ydGZv bGlvIGhlbH BzIG1pdGln YXRlIHJpc2 tzIGFuZCBh bGxvd3MgdG hlIGNvbXBh bnkgdG8gYm VuZWZpdCBm cm9tIHRoZS BkaWZmZXJl bnQgZ3Jvd3 RoIHRyZW5k cyBhbmQgcm VndWxhdG9y eSBsYW5kc2 NhcGVzIGFj cm9zcyB0aG VzZSBzZWN0 b3JzLjxicj 5JbiBhZGRp dGlvbiwgR1 NLIGhhcyBh IHN0cm9uZy Bmb2N1cyBv biBzdXN0YW luYWJpbGl0 eSBhbmQgc2 9jaWFsIHJl c3BvbnNpYm lsaXR5LCBp bnRlZ3JhdG luZyB0aGVz ZSBwcmluY2 lwbGVzIGlu dG8gaXRzIG J1c2luZXNz IG9wZXJhdG lvbnMgYW5k IGRlY2lzaW 9uLW1ha2lu Zy4gVGhlIG NvbXBhbnkg aXMgYWxzby Bjb21taXR0 ZWQgdG8gcH JpY2luZyBp dHMgcHJvZH VjdHMgcmVz cG9uc2libH kgYW5kIGVu c3VyaW5nIG FjY2VzcyB0 byBtZWRpY2 luZXMgaW4g ZGV2ZWxvcG luZyBjb3Vu dHJpZXMu
Interesting facts about the company
GlaxoSmithKline

πŸ“ˆ Want to read more about GlaxoSmithKline?

Sign up for free or log in

πŸ™Œ Join now to get "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" at no cost

CiAgICAgIC AgICAgIDxk aXYgc3R5bG U9J3dpZHRo OiAxMDAlOy BkaXNwbGF5 OiBmbGV4Oy BqdXN0aWZ5 LWNvbnRlbn Q6IGNlbnRl cjsnPgogIC AgICAgICAg ICAgICAgPG RpdiBzdHls ZT0nCiAgIC AgICAgICAg ICAgICAgIC AgZGlzcGxh eTogZmxleD sKICAgICAg ICAgICAgIC AgICAgICBh bGlnbi1pdG VtczogY2Vu dGVyOwogIC AgICAgICAg ICAgICAgIC AgIGJhY2tn cm91bmQtY2 9sb3I6ICNm MGY0Zjg7Ci AgICAgICAg ICAgICAgIC AgICAgYm9y ZGVyOiAxcH ggc29saWQg I2QxZTNmMD sKICAgICAg ICAgICAgIC AgICAgICBi b3JkZXItcm FkaXVzOiAx MHB4OwogIC AgICAgICAg ICAgICAgIC AgIHBhZGRp bmc6IDEwcH g7CiAgICAg ICAgICAgIC AgICAgICAg bWFyZ2luOi AyMHB4IDA7 CiAgICAgIC AgICAgICAg ICAgICAgZm 9udC1mYW1p bHk6ICJTZW dvZSBVSSIs IFJvYm90by wgc2Fucy1z ZXJpZjsKIC AgICAgICAg ICAgICAgIC AgICBib3gt c2hhZG93Oi AwIDJweCA2 cHggcmdiYS gwLCAwLCAw LCAwLjA1KT sKICAgICAg ICAgICAgIC AgICAgICBt YXgtd2lkdG g6IDkwMHB4 OwogICAgIC AgICAgICAg ICAgICAgIH dpZHRoOiAx MDAlOyc+Cg ogICAgICAg ICAgICAgIC AgICAgIDxp bWcgc3JjPS Jhc3NldHMv bG9nb3Mvbn VkRDBMNmt1 eFY4RFdsVX RKQjgud2Vi cCIgYWx0PS JHbGF4b1Nt aXRoS2xpbm UiIHRpdGxl PSJHbGF4b1 NtaXRoS2xp bmUiICBjbG Fzcz0iaW1n LWZsdWlkIi BoZWlnaHQ9 OTAgd2lkdG g9OTAgbG9h ZGluZz0nbG F6eScgc3R5 bGU9J2Jvcm Rlci1yYWRp dXM6IDZweD snPgoKICAg ICAgICAgIC AgICAgICAg ICA8ZGl2IH N0eWxlPSdm bGV4OiAxOy B0ZXh0LWFs aWduOiBjZW 50ZXI7IG1h cmdpbi1sZW Z0OiA1cHg7 Jz4KICAgIC AgICAgICAg ICAgICAgIC AgICAgPHAg c3R5bGU9J2 ZvbnQtc2l6 ZTogMjZweD sgY29sb3I6 ICMzMzM7IG 1hcmdpbi1i b3R0b206ID E1cHg7Jz4K ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIPCf k4ggV2FudC B0byByZWFk IG1vcmUgYW JvdXQgR2xh eG9TbWl0aE tsaW5lPwog ICAgICAgIC AgICAgICAg ICAgICAgIC A8L3A+Cgog ICAgICAgIC AgICAgICAg ICAgICAgIC A8YSBocmVm PSdpbmRleC 5waHA/cGFn ZT1zaWdudX AnIHN0eWxl PScKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IGJhY2tncm 91bmQtY29s b3I6ICMwMD dCRkY7CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBjb2xv cjogI2ZmZj sKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIH BhZGRpbmc6 IDEwcHggMj BweDsKICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIGJvcmRl ci1yYWRpdX M6IDVweDsK ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIHRl eHQtZGVjb3 JhdGlvbjog bm9uZTsKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIGZvbn Qtd2VpZ2h0 OiBib2xkOw ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgbW FyZ2luLXJp Z2h0OiAxMH B4OwogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgdHJhbnNp dGlvbjogYm Fja2dyb3Vu ZC1jb2xvci AwLjNzIGVh c2U7JwogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgb25tb3 VzZW92ZXI9 J3RoaXMuc3 R5bGUuYmFj a2dyb3VuZE NvbG9yPSIj MDA1NmIzIi cKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIG 9ubW91c2Vv dXQ9J3RoaX Muc3R5bGUu YmFja2dyb3 VuZENvbG9y PSIjMDA3Qk ZGIic+CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBTaWdu IHVwIGZvci BmcmVlCiAg ICAgICAgIC AgICAgICAg ICAgICAgID wvYT4KCiAg ICAgICAgIC AgICAgICAg ICAgICAgID xzcGFuIHN0 eWxlPSdtYX JnaW46IDAg OHB4OyBjb2 xvcjogIzU1 NTsnPm9yPC 9zcGFuPgoK ICAgICAgIC AgICAgICAg ICAgICAgIC AgPGEgaHJl Zj0naW5kZX gucGhwP3Bh Z2U9bG9naW 4nIHN0eWxl PScKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IGNvbG9yOi AjMDA3QkZG OwogICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg dGV4dC1kZW NvcmF0aW9u OiB1bmRlcm xpbmU7CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBmb250 LXdlaWdodD ogNTAwOyc+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBs b2cgaW4KIC AgICAgICAg ICAgICAgIC AgICAgICAg PC9hPgoKCi AgICAgICAg ICAgICAgIC AgICAgICAg IDxwIHN0eW xlPSdtYXJn aW4tdG9wOi AxNXB4OyBm b250LXNpem U6IDEzcHg7 IGZvbnQtd2 VpZ2h0OiBi b2xkOyBjb2 xvcjogI2Qz MmYyZjsnPg ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAg8J +TliBHZXQg aW5zaWdodH MgZnJvbSA8 aT4iVGhlIE NoZWNrbGlz dCBWYWx1ZS BJbnZlc3Rv ciDigJQgQS BTbWFydGVy IFdheSB0by BQaWNrIFN0 b2NrcyI8L2 k+IG5vdyEK ICAgICAgIC AgICAgICAg ICAgICAgIC AgPC9wPgoK ICAgICAgIC AgICAgICAg ICAgICAgIC AgPCEtLQog ICAgICAgIC AgICAgICAg ICAgICAgIC A8ZGl2IHN0 eWxlPSdtYX JnaW4tdG9w OiAxMnB4Oy Bmb250LXNp emU6IDEzcH g7IGNvbG9y OiAjNDQ0Oy c+CiAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIC BTaWduIHVw IG5vdyBhbm QgZ2V0IG91 ciBmcmVlIG VCb29rIAog ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgPGI+ VGhlIENoZW NrbGlzdCBW YWx1ZSBJbn Zlc3RvciDi gJQgQSBTbW FydGVyIFdh eSB0byBQaW NrIFN0b2Nr czwvYj4KIC AgICAgICAg ICAgICAgIC AgICAgICAg PC9kaXY+Ci AgICAgICAg ICAgICAgIC AgICAgICAg IC0tPgogIC AgICAgICAg ICAgICAgIC AgICAgICA8 IS0tCiAgIC AgICAgICAg ICAgICAgIC AgICAgIDxk aXYgc3R5bG U9J21hcmdp bi10b3A6ID E2cHg7IGZv bnQtc2l6ZT ogMTRweDsg Y29sb3I6IC M0NDQ7IGZv bnQtZmFtaW x5OiAtYXBw bGUtc3lzdG VtLCBCbGlu a01hY1N5c3 RlbUZvbnQs IFNlZ29lIF VJLCBSb2Jv dG8sIEhlbH ZldGljYSBO ZXVlLCBzYW 5zLXNlcmlm OyBsaW5lLW hlaWdodDog MS42Oyc+Ci AgICAgICAg ICAgICAgIC AgICAgICAg ICAgICBIYX ZlIHlvdSBo ZWFyZCBhYm 91dCBvdXIg c2hvcnQgPH N0cm9uZyBz dHlsZT0nZm 9udC13ZWln aHQ6IDYwMD snPkRhaWx5 IFZpZGVvIE 5ld3NsZXR0 ZXI8L3N0cm 9uZz4/CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICA8YSBo cmVmPSdodH RwczovL3d3 dy5pbnNpZ2 h0ZnVsdmFs dWUuY29tL2 5ld3NsZXR0 ZXIucGhwJy B0YXJnZXQ9 J19ibGFuay cgc3R5bGU9 J2NvbG9yOi AjMDA3QkZG OyB0ZXh0LW RlY29yYXRp b246IG5vbm U7IGZvbnQt d2VpZ2h0Oi A1MDA7IG1h cmdpbi1sZW Z0OiA2cHg7 Jz4KICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgICBGaW 5kIG91dCBt b3JlCiAgIC AgICAgICAg ICAgICAgIC AgICAgICAg ICA8L2E+Ci AgICAgICAg ICAgICAgIC AgICAgICAg IDwvZGl2Pg ogICAgICAg ICAgICAgIC AgICAgICAg ICAtLT4KIC AgICAgICAg ICAgICAgIC AgICA8L2Rp dj4KICAgIC AgICAgICAg ICAgIDwvZG l2PgogICAg ICAgICAgIC A8L2Rpdj4K ICAgICAgIC AgICAgCiAg ICAgICAgCi AgICAgICAg PHNwYW4gY2 xhc3M9J2Js dXJyZWQtdG V4dCc+CiAg ICAgICAgIC AgIE1TNGdS MnhoZUcgOV RiV2wwYUV0 cyBhVzVsSU dseklHIEVn UW5KcGRHbH ogYUNCdGRX eDBhVyA1aG RHbHZibUZz IElIQm9ZWE p0WVcgTmxk WFJwWTJGcy BJR052YlhC aGJuIGtzSU hkcGRHZ2cg YUdWaFpIRj FZWCBKMFpY SnpJR2x1IE lFeHZibVJ2 Ymkgd2dSVz VuYkdGdSBa QzQ4WW5JK0 1pIDRnVkdo bElHTnYgYl hCaGJua2dh RyBGeklHRW diRzl1IFp5 Qm9hWE4wYj MgSjVMQ0Jr WVhScCBibW NnWW1GamF5 IEIwYnlCaE lIQm8gWVhK dFlXTjVJRy A5d1pXNWxa Q0JpIGVTQk tiM05sY0cg Z2dUbUYwYU dGdSBJR2x1 SUU1bGR5IE JhWldGc1lX NWsgSUdsdU lERTRNeiBB dVBHSnlQak 11IElGUm9a U0JqYjIgMX dZVzU1SUhk aCBjeUJtYj NKdFlXIHhz ZVNCbWIzVn UgWkdWa0lH bHVJRCBFNU 1EWWdZbmtn IFNtOXpaWE JvSUUgVmtk MkZ5WkNCTy BZWFJvWVc0 Z1lXIDVrSU docGN5Qmkg Y205MGFHVn lMVyBsdUxX eGhkeXdnIF ZHaHZiV0Z6 SUUgaHZiR3 h2ZDJGNSBM Q0JoY3lCaE lIIE50WVd4 c0lIQm8gWV hKdFlXTjVJ RyBsdUlFeH ZibVJ2IGJp NDhZbkkrTk MgNGdWR2hs SUc1aCBiV1 VnUjJ4aGVH IDhnWTI5dF pYTWcgWm5K dmJTQjBhRy BVZ1ptbHlj M1FnIGNISn ZaSFZqZEMg QjBhR0YwSU hSbyBaU0Jq YjIxd1lXID U1SUhCeWIy UjEgWTJWa0 xDQjNhRyBs amFDQjNZWE 1nIFlTQmtj bWxsWkMgQn RhV3hySUhC eSBiMlIxWT NRZ1kyIEZz YkdWa0lFZH MgWVhodkxq eGljaiA0MU xpQkhiR0Y0 IGJ5QnRaWE puWlcgUWdk MmwwYUNCWC BaV3hzWTI5 dFpTIEJwYm lBeE9UazEg SUhSdklHWn ZjbSAwZ1Iy eGhlRzhnIF YyVnNiR052 YlcgVXNJSG RvYVdObyBJ SFJvWlc0Z2 JXIFZ5WjJW a0lIZHAgZE dnZ1UyMXBk RyBoTGJHbH VaU0JDIFpX VmphR0Z0SU cgbHVJREl3 TURBZyBkRz hnWm05eWJT IEJIYkdGNG IxTnQgYVhS b1MyeHBibS BVdVBHSnlQ all1IElFZH NZWGh2VTIg MXBkR2hMYk dsdSBaU0Jw Y3lCamRYIE p5Wlc1MGJI a2cgYjI1bE lHOW1JSCBS b1pTQnNZWE puIFpYTjBJ SEJvWVggSn RZV05sZFhS cCBZMkZzSU dOdmJYIEJo Ym1sbGN5Qn AgYmlCMGFH VWdkMiA5eW JHUXNJSGRw IGRHZ2djbV YyWlcgNTFa U0J2WmlCdi BkbVZ5SUNR ME1TIEJpYV d4c2FXOXUg SUdsdUlESX dNaiBBdVBH SnlQamN1IE lGUm9aU0Jq YjIgMXdZVz U1SUdseiBJ R0VnYldGcW IzIElnY0hK dlpIVmogWl hJZ2IyWWdk bSBGalkybH VaWE1zIElH TnZibk4xYl cgVnlJR2hs WVd4MCBhR0 5oY21VZ2NI IEp2WkhWam RITXMgSUdG dVpDQndjbS BWelkzSnBj SFJwIGIyNG diV1ZrYVcg TnBibVZ6TE NCaCBibVFn YVhRZ2FHIE Z6SUdFZ2NI SmwgYzJWdV kyVWdhVyA0 Z2IzWmxjaU F4IE5UQWdZ MjkxYm4gUn lhV1Z6TGp4 aSBjajQ0TG lCSGJHIEY0 YjFOdGFYUm 8gUzJ4cGJt VWdhRyBGek lHRWdiRzl1 IFp5Qm9hWE 4wYjMgSjVJ RzltSUhOcC BaMjVwWm1s allXIDUwSU hOamFXVnUg ZEdsbWFXTW dZVyBOb2FX VjJaVzFsIG JuUnpMQ0Jw Ym0gTnNkV1 JwYm1jZyBk R2hsSUdSbG RtIFZzYjNC dFpXNTAgSU c5bUlIUnla VyBGMGJXVn VkSE1nIFpt OXlJRWhKVm kgd2dhVzVt YkhWbCBibn BoTENCaGJt IFFnYldGc1 lYSnAgWVM0 OFluSStPUy A0Z1ZHaGxJ R052IGJYQm hibmtnYUcg RnpJR0ZzYz I4ZyBZbVZs YmlCcGJuIF p2YkhabFpD QnAgYmlCel pYWmxjbSBG c0lHaHBaMm d0IGNISnZa bWxzWlMgQn NaV2RoYkNC aiBZWE5sY3 l3Z2FXIDVq YkhWa2FXNW 4gSUdFZ0pE TWdZbSBsc2 JHbHZiaUJ6 IFpYUjBiR1 Z0WlcgNTBJ R1p2Y2lCcC BiR3hsWjJG c2JIIGtnY0 hKdmJXOTAg YVc1bklHTm xjbiBSaGFX NGdaSEoxIF ozTWdZVzVr SUcgRWdjMl YwZEd4bCBi V1Z1ZENCM2 FYIFJvSUhS b1pTQlYgVX lCbmIzWmxj bSA1dFpXNT BJR1p2IGNp QWtOelV3SU cgMXBiR3hw YjI0ZyBabT l5SUcxaGJu IFZtWVdOMG RYSnAgYm1j Z1lXNWtJSC BGMVlXeHBk SGtnIFkyOX VkSEp2YkMg QndjbTlpYk dWdCBjeUJo ZENCaElIIE JzWVc1MElH bHUgSUZCMV pYSjBieSBC U2FXTnZMan hpIGNqNHhN QzRnU1cgNG dNakF5TUN3 ZyBSMnhoZU c5VGJXIGww YUV0c2FXNW wgSUdKbFky RnRaUyBCMG FHVWdabWx5 IGMzUWdjR2 hoY20gMWhZ MlYxZEdsai BZV3dnWTI5 dGNHIEZ1ZV NCMGJ5Qncg YkdWa1oyVW dkRyA4Z2JX RnJaU0JwIG RITWdZMkZ5 WW0gOXVJR1 p2YjNSdyBj bWx1ZENCdV pYIFF0ZW1W eWJ5QmkgZV NBeU1EVXdM aiB4aWNqNH hNUzRnIFIy eGhlRzlUYl cgbDBhRXRz YVc1bCBJR2 hoY3lCaElI IE4wY205dV p5QmogYjIx dGFYUnRaVy A1MElIUnZJ R052IGNuQn ZjbUYwWlMg QnpiMk5wWV d3ZyBjbVZ6 Y0c5dWMyIG xpYVd4cGRI a3MgSUhkcG RHZ2dZUyBC bWIyTjFjeU J2IGJpQnBi WEJ5YjMgWn BibWNnWjJ4 diBZbUZzSU dobFlXIHgw YUN3Z2NtVm sgZFdOcGJt Y2dhWCBSek lHVnVkbWx5 IGIyNXRaVz UwWVcgd2dh VzF3WVdOMC BMQ0JoYm1R Z2MzIFZ3Y0 c5eWRHbHUg WnlCamIyMX RkVyA1cGRH bGxjeUIzIG FHVnlaU0Jw ZEMgQnZjR1 Z5WVhSbCBj eTQ4WW5JK0 1UIEl1SUZS b1pTQmogYj Ixd1lXNTVJ RyBoaGN5Qm hJR1JwIGRt VnljMlVnZD IgOXlhMlp2 Y21ObCBMQ0 IzYVhSb0lH IDkyWlhJZ0 1UQXcgTERB d01DQmxiWC BCc2IzbGxa WE1nIGQyOX liR1IzYVcg UmxJR0Z1Wk NCaCBJSE4w Y205dVp5IE JtYjJOMWN5 QnYgYmlCa2 FYWmxjbiBO cGRIa2dZVz VrIElHbHVZ MngxYzIgbH ZiaUJwYmlC MCBhR1VnZD I5eWEzIEJz WVdObExqeG kgY2o0eE15 NGdSMiB4aG VHOVRiV2ww IGFFdHNhVz VsSUcgaGhj eUJoSUhKdi BZblZ6ZENC d2FYIEJsYk dsdVpTQnYg WmlCdVpYY2 daSCBKMVoz TWdZVzVrIE lIUnlaV0Yw YlcgVnVkSE 1nYVc0ZyBa R1YyWld4dm NHIDFsYm5R c0lIZHAgZE dnZ2IzWmxj aSBBMU1DQm pZVzVrIGFX UmhkR1VnZE cgaGxjbUZ3 YVdWeiBJR2 x1SUhaaGNt IGx2ZFhNZ2 MzUmggWjJW eklHOW1JRy BOc2FXNXBZ MkZzIElIUn lhV0ZzY3kg NDhZbkkrTV RRdSBJRlJv WlNCamIyID F3WVc1NUlH aGggY3lCaE lITjBjbSA5 dVp5QndjbV Z6IFpXNWpa U0J2YmkgQn piMk5wWVd3 ZyBiV1ZrYV dFc0lIIGRw ZEdnZ2IzWm wgY2lBNE5T d3dNRCBBZ1 ptOXNiRzkz IFpYSnpJRz l1SUYgUjNh WFIwWlhJZy BZVzVrSUdG amRHIGwyWl NCaFkyTnYg ZFc1MGN5Qn ZiaSBCTWFX NXJaV1JKIG Jpd2dSbUZq WlcgSnZiMn NzSUdGdSBa Q0JKYm5OMF lXIGR5WVcw dVBHSnkgUG pFMUxpQkhi RyBGNGIxTn RhWFJvIFMy eHBibVVnYU cgRnpJSEps WTJWcCBkbV ZrSUc1MWJX IFZ5YjNWek lHRjMgWVhK a2N5QmhibS BRZ2NtVmpi MmR1IGFYUn BiMjRnWm0g OXlJR2wwY3 lCMyBiM0py TENCcGJtIE 5zZFdScGJt Y2cgWW1WcG JtY2dibSBG dFpXUWdiMj VsIElHOW1J SFJvWlMgRG lnSnhYYjNK cyBaT0tBbV hNZ1RXIDl6 ZENCRmRHaH AgWTJGc0lF TnZiWCBCaG JtbGxjK0tB IG5TQmllU0 IwYUcgVWdS WFJvYVhOdy BhR1Z5WlNC SmJuIE4wYV hSMWRHVWcg Wm05eUlERX hJRyBOdmJu TmxZM1YwIG FYWmxJSGxs WVggSnpMZz 09CiAgICAg ICAgPC9zcG FuPgogICAg ICAgIAogIC AgICAgIA==
See Company Q&A
GlaxoSmithKline

πŸ“Š Get full analytics about GlaxoSmithKline

Sign up for free or log in

🎁 Free download! "The Checklist Value Investor β€” A Smarter Way to Pick Stocks"

© 2024 - 2025 InsightfulValue.com. All rights reserved. Newsletter
Legal